Microsatellite Instability, KRAS Mutations and Cellular Distribution of TRAIL-Receptors in Early Stage Colorectal Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Kriegl, Lydia ^a   Jung, Andreas ^a   Horst, David ^a   Rizzani, Antonia ^b   Jackstadt, Rene ^a   Hermeking, Heiko ^a   Gallmeier, Eike ^b   Gerbes, Alexander L ^b   Kirchner, Thomas ^a   Göke, Burkhard ^b   de Toni, Enrico N ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; K RAS PROTEIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATION; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOCARCINOMA; AGED; CADHERINS; CELL MEMBRANE; COLORECTAL NEOPLASMS; DNA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84871414682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051654     Document Type: Article

References (40)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010) Colorectal cancer. Lancet 375: 1030-1047.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
3. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. (2010) Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 28: 4706-4713.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
5. Johnstone RW, Frew AJ, Smyth MJ, (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
6. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, et al. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161-169.
7. Walczak H, Koschny R, Willen D, Schader MB, Sykora J, et al. (2006) The TRAIL Receptor-Ligand System: Biochemistry of Apoptosis Induction, Therapeutic potential for Cancer Treatment and Physiological Functions. In: Debatin KM, Fulda S, editors. Apoptosis and Cancer Therapy. Weinheim. pp. 31-74.
8. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, et al. (2010) Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 16: 5529-5538.
9. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, et al. (2008) OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 14: 4713-4718.
10. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, et al. (2002) Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8: 3734-3740.
11. Van Geelen CM, de Vries EG, de Jong S, (2004) Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7: 345-358.
12. Van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, et al. (2006) Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24: 4998-5004.
13. Ullenhag GJ, Mukherjee A, Watson NF, Al Attar AH, Scholefield JH, et al. (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13: 5070-5075.
14. Sobin LH, Wittiking C (2010) TMN classification of malignant tumours (7th edn.). London: Wiley and sons.
15. Niemoller O, Belka C, (2009) Targeting death-receptors in radiation therapy. Results Probl Cell Differ 49: 219-239.
16. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, et al. (2004) Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res 10: 7884-7895.
17. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847.
18. Zhang Y, Zhang B, (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6: 1861-1871.
19. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A, (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.
20. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421.
21. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, et al. (2007) K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203: 489-497.
22. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, et al. (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257.
23. Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Van Damme N, et al. (2008) Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn 10: 154-159.
24. Jaitner S, Reiche JA, Schaffauer AJ, Hiendlmeyer E, Herbst H, et al. (2012) Human telomerase reverse transcriptase (hTERT) is a target gene of beta-catenin in human colorectal tumors. Cell Cycle 11: 3331-3338.
25. Abubaker J, Bavi P, Al Haqawi W, Sultana M, Al Harbi S, et al. (2009) Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 219: 435-445.
26. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226.
27. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, et al. (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29: 1261-1270.
28. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, et al. (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103: 863-875.
29. Yue HH, Diehl GE, Winoto A, (2005) Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 12: 94-97.
30. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, et al. (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118: 100-110.
31. Ohira M, Ohdan H, Mitsuta H, Ishiyama K, Tanaka Y, et al. (2006) Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 82: 1712-1719.
32. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, et al. (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94-100.
33. Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, et al. (2010) Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer 9: 203.
34. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, et al. (2001) Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61: 4942-4946.
35. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, et al. (2005) Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11: 5188-5194.
36. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512.
37. Soria JC, Smit E, Khayat D, Besse B, Yang X, et al. (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28: 1527-1533.
38. Jeng YM, Hsu HC, (2002) Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett 181: 205-208.
39. Schulze-Bergkamen H, Weinmann A, Moehler M, Siebler J, Galle PR, (2009) Novel ways to sensitise gastrointestinal cancer to apoptosis. Gut 58: 1010-1024.
40. Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, et al. (2009) Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 15: 5457-5465.